Last checked at 12 Sep 2019 15:19
12 September 2019
Provexis plc
("Provexis" or the "Company")
Director / PDMR notification
Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that Ian Ford, CEO and CFO, purchased a total of 5,000,000 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") on 12 September 2019 at an average price of 0.338 pence per Ordinary Share.
Following this purchase, Mr Ford has a total beneficial interest in 10,000,000 Ordinary Shares, equivalent to 0.50% of the Company's issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them are set out below pursuant to the EU Market Abuse regulation.
1
| Details of the person discharging managerial responsibilities / person closely associated | |||||
a)
| Name | Ian Ford (Director and PDMR) - shares acquired on behalf of Mr Ford's children (under the age of 18) who are persons closely associated with Mr Ford
| ||||
2
| Reason for the notification | |||||
a)
| Position/status
| See 1a) above
| ||||
b)
| Initial notification / Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a)
| Name
| PROVEXIS PLC | ||||
b)
| LEI
| 21380042E3Y3N9VZ6N48
| ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 0.1p each
ISIN: GB00B0923P27
| ||||
b)
| Nature of the transaction
| Purchase of ordinary shares | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information - Aggregated volume - Price
|
5,000,000 shares
Average price of 0.338 pence per share
| ||||
e)
| Date of the transaction
| 12 September 2019 | ||||
f)
| Place of the transaction
| London Stock Exchange, AIM Market | ||||
For further information please contact:
Provexis plc Dawson Buck, Chairman Ian Ford, CEO & CFO
| Tel: 07490 391888 enquiries@provexis.com |
Allenby Capital Limited Nick Naylor / Liz Kirchner | Tel: 020 3328 5656
|
Notes for editors
About Provexis plc
AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.
Provexis was founded in 1999 and is headquartered in Reading, Berkshire.
Provexis shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.
For further information, please visit www.provexis.com and www.fruitflowplus.com.